Prostate Cancer Screening (PDQ®)–Health Professional Version
SECTIONS
- Overview
- Description of the Evidence
- Harms of Screening
- Changes to This Summary (06/23/2017)
- About This PDQ Summary
- View All Sections
Changes to This Summary (06/23/2017)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added text about an extended follow-up analysis for mortality, with median follow-up of almost 15 years, that showed prostate cancer mortality rates of 47.8 per 100,000 person-years in the intervention group and 46.0 per 100,000 person-years in the usual-care group, given a rate ratio of 1.04. An analysis of nonprotocol screening during the postscreening phase of the trial showed that 78.7% of men in the usual-care group and 80.3% of men in the intervention group had received a prostate-specific antigen (PSA) test within the past 3 years, and that 85.9% of men in the usual-care group and 98.9% of men in the intervention group had ever had a PSA test (cited Pinsky et al. as reference 36).
This summary is written and maintained by the PDQ Screening and Prevention Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.
No hay comentarios:
Publicar un comentario